Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via...
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
About this item
Full title
Author / Creator
Wang, Yao , Tong, Chuan , Dai, Hanren , Wu, Zhiqiang , Han, Xiao , Guo, Yelei , Chen, Deyun , Wei, Jianshu , Ti, Dongdong , Liu, Zongzhi , Mei, Qian , Li, Xiang , Dong, Liang , Nie, Jing , Zhang, Yajing and Han, Weidong
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Insufficient eradication capacity and dysfunction are common occurrences in T cells that characterize cancer immunotherapy failure. De novo DNA methylation promotes T cell exhaustion, whereas methylation inhibition enhances T cell rejuvenation in vivo. Decitabine, a DNA methyltransferase inhibitor approved for clinical use, may provide a means of m...
Alternative Titles
Full title
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_933c244786634cf58dfafd51abcccf81
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_933c244786634cf58dfafd51abcccf81
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-020-20696-x
